Cas No.Product NameDescription
936091-26-8TG101348TG-101348 is a potent, highly selective JAK2 inhibitor.
941678-49-5RuxolitinibRuxolitinib is an orally bioavailable, potent and selective inhibitor of Janus-associated kinase (JAK) 1 and 2, with IC50 to be 2.7, 4.5 and 332 nM for JAK1, JAK2 and JAK3 respectively.
936091-14-4TG101209TG101209 is a potent and small molecule JAK2-selective kinase inhibitor with IC50 of 6, 25, 17 and 169 nM for JAK2, FLT3, RET and JAK3, respectively.
1134099-70-9/83280-65-3BBI608 BBI608 is an orally available cancer cell stemness inhibitor with potential antineoplastic activity.
501919-59-1S31-201NSC 74859 (S3I-201) inhibits Stat3-Stat3 complex formation and Stat3 DNA-binding (IC50 =86 ±33μM) and transcriptional activities.
477600-75-2TofacitinibTasocitinib also known as CP690550 is an JAK kinase inhibitor.
35825-57-1CryptotanshinoneCryptotanshinone (CPT) is a STAT3 inhibitor with IC50 of 4.6 μM, strongly inhibits phosphorylation of STAT3 Tyr705, with a small effect on STAT3 Ser727, but none against STAT1 nor STAT5.
1003580-86-6S 31-M2001
857064-38-1WP1066WP1066 is a novel inhibitor of JAK2 and STAT3 with IC50 of 2.30 μM and 2.43 μM in HEL cells; shows activity to JAK2, STAT3, STAT5, and ERK1/2, but not JAK1 and JAK3.
218600-53-4NSC713200Bardoxolone Methyl is an IKK inhibitor, showing potent proapoptotic and anti-inflammatory activities.
1187594-09-7BaricitinibBaricitinib, also known as INCB028050 or LY3009104, is a selective orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM).
101152-94-7F2207Milnacipran hydrochloride is a serotonin-norepinephrine reuptake inhibitor (SNRI) used in the clinical treatment of fibromyalgia.
134678-17-4LamivudineLamivudine is a potent nucleoside analog reverse transcriptase inhibitor with an IC50 of 2.7 mM.
195371-52-9JAK2 Inhibitor V Z3 Z3 is a novel specific inhibitor of Jak2 tyrosine kinase. Z3 inhibited Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner but was not cytotoxic to cells at concentrations that inhibited kinase activity.
111358-88-4LestaurtinibPotent JAK2, FLT3 and TrkA inhibitor (IC50 values are 0.9, 3 and < 25 nM respectively) that prevents STAT5 phosphorylation (IC50 = 20 - 30 nM).
4452-06-6ZM 449829JAK3 Inhibitor V is a potent, selective inhibitor of JAK3 (Janus tyrosine kinase 3) which binds competitively to the JAK3 ATP site.
1271022-90-2BMS-911543BMS-911543 is a potent and selective inhibitor of JAK2 with IC50 of 1.1?nM, ~350-, 75- and 65-fold selective to JAK1, JAK3 and TYK2, respectively.
540737-29-9Tofacitinib citrate Tasocitinib also known as CP690550 is an JAK kinase inhibitor.
1206101-20-3GLPG0634 analogGLPG0634 is an orally-available, selective inhibitor of JAK1 (Janus kinase 1) being developed by Galapagos for the treatment of rheumatoid arthritis and potentially other inflammatory diseases.
945755-56-6XL019 XL019 is a potent and selective JAK2 inhibitor.

First Previous Next End   Jump to  Page
Cell Cycle/Checkpoint
Angiogenesis/Tyrosine Kinase
Apoptosis Pathway
Aurora/Ksp Pathway
MAPK Pathway
Hormone Pathay
Proteases/HSP90/HSP70 Pathway
Wnt/Hedgehog/Notch Pathway
Jak/Stat Pathway
Ca/cAMP/Lipid Signaling Pathway
Neuro Signaling Pathway
TGF-beta/Smad Signaling Pathway
GPCR Pathway
Ion channel Pathway
Cytochrome P450 Pathway
Others Pathway